SurModics Reports Second Quarter Fiscal 2013 Results

SurModics Reports Second Quarter Fiscal 2013 Results

  • GAAP Revenue Grows 12%

  • Continuing Operations GAAP EPS Increases to $0.23

  • Non-GAAP Continuing Operations EPS Increases 25% to $0.20

  • Revenue and EPS Ranges for Full Year Reaffirmed

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (NAS: SRDX) , a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 second quarter.

Second Quarter Revenue and Earnings Summary


Revenue for the second quarter totaled $13.7 million, a 12% increase from $12.2 million reported in the fiscal 2012 second quarter. Diluted earnings per share from continuing operations totaled $0.23 versus $0.11 in the prior-year period. On a non-GAAP basis, earnings per share from continuing operations were $0.20 in the 2013 second quarter.

Fiscal 2013 second quarter earnings per share include $0.03 per share of income tax benefits from capital loss carrybacks and retroactively reinstated R&D tax credits. Further, the prior-year quarterly period included an impairment charge related to a strategic investment of $0.8 million, or $0.05 per share.

Commenting on the results, SurModics' President and Chief Executive Officer, Gary Maharaj said, "I am pleased with our team's performance in the second quarter. We delivered double-digit gains in both revenue and earnings per share. Our strategy of focusing on SurModics' core businesses continued to drive strong results in our two businesses. Both our Medical Device and In Vitro Diagnostic segments are executing our strategic initiatives as planned, and both reported solid year-over-year revenue gains."

Medical Device Highlights

Revenue for the Medical Device business unit, which includes hydrophilic coatings and device drug delivery technologies, was $9.7 million, an 11% increase from $8.8 million in the fiscal second quarter of last year. Second quarter hydrophilic coating revenue increased 10% to $9.6 million compared with the year ago period. Medical Device generated $4.8 million of operating income during the quarter, a 16% increase from fiscal 2012.

Additional highlights include:

  • Three medical device customers launching new products utilizing SurModics hydrophilic coatings; and

  • Double-digit hydrophilic royalty growth in the key neurovascular and transcatheter valves growth segments.

In Vitro Diagnostics Highlights

For the second quarter, revenue for the In Vitro Diagnostics (IVD) business unit totaled $4.0 million, up 15% compared with the second quarter of fiscal 2012. The IVD business unit generated $1.3 million of operating income, the same as the year ago period, as the increase in gross margin from higher sales did not offset the higher operating expenses that stemmed from increased allocation of corporate expense, as well as additional hiring needed to support growth.

Additional highlights include:

  • 10 consecutive quarters of year-over-year product revenue growth; and

  • The addition of 16 new diagnostic test kit customers.

Discontinued Operations

During the fiscal 2013 second quarter, the Company realized discontinued operations income of almost $0.7 million, net of tax, primarily from the settlement of job incentive obligations with the City of Birmingham, Alabama.

Balance Sheet

As of March 31, 2013, the Company has $63.2 million of cash and investments. SurModics purchased 105,097 common shares for $2.7 million in the fiscal 2013 second quarter.

Full-Year Revenue and Earnings Outlook

SurModics reaffirms its previously stated fiscal 2013 outlook for revenue and earnings per share from continuing operations. Revenue from continuing operations is expected to be in the range of $55 million to $58 million. GAAP earnings per share from continuing operations are expected to be in the range of $ $0.86 to $0.99 per share. Per share information does not take into account any share repurchases that might occur during the balance of fiscal 2013. For fiscal 2012, SurModics reported revenue of $51.9 million and earnings per share from continuing operations of $0.58.

Maharaj concluded "We are off to a solid start in fiscal 2013 and remain confident in our ability to make progress on our stated strategic, operational and financial goals for the full year."

Correction of Carrying Value of Strategic Investment in Prior Period

The accompanying financial tables reflect a $1.2 million adjustment to increase the carrying value of our strategic investments, recorded within other assets, and stockholders' equity in the prior period balance sheet. This adjustment corrects and reduces an other than temporary impairment charge as of September 30, 2010, which was previously recorded during the fiscal fourth quarter ended September 30, 2010. The original other than temporary impairment charge did not sufficiently evaluate the impact of the proposed sale of a strategic investment subsidiary to an unrelated third party, in evaluating the value of the strategic investment. This transaction was consummated on February 1, 2011. The impact of this adjustment was not deemed to be material to the results of operations, total assets or stockholders' equity for the previously reported periods. Further details of this adjustment will be included in our Quarterly Report on Form 10-Q for the period ended March 31, 2013.

Live Webcast

SurModics will host a webcast at 5 p.m. ET (4 p.m. CT) today to discuss second quarter results. To access the webcast, go to the Investors section of the Company's website at www.surmodics.com and click on the webcast icon. A replay of the second quarter conference call will be available by dialing 800-406-7325 and entering conference call ID passcode 4593304. The audio replay will be available beginning at 7 p.m. ET on Tuesday, May 7, 2013, until 7 p.m. ET on Tuesday, May 14, 2013.

About SurModics, Inc.

SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit http://www.surmodics.com. The content of SurModics' website is not part of this press release or part of any filings that the Company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our ability to achieve sustainable long-term growth and value creation, our expectations regarding the Company's performance in the near- and long-term, including our revenue and earnings expectations for fiscal 2013, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and our ability to achieve our corporate goals; (2) possible adverse market conditions and possible adverse impacts on our cash flows, and (3) the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2012, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Use of Non-GAAP Financial Information

In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, SurModics is reporting non-GAAP financial results including non-GAAP net income and non-GAAP diluted net income per share. We believe that these non-GAAP measures provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payout under our executive compensation programs. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact upon our reported financial results. As such, these non-GAAP measures presented should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.

SurModics, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(in thousands, except per share data)

Three Months Ended
March 31,

Six Months Ended
March 31,

2013

2012

2013

2012

(Unaudited)

(Unaudited)

Revenue

Royalties and license fees

$

6,951

$

6,283

$

14,467

$

12,893

Product sales

5,758

5,067

11,111

9,701

Research and development

986

860

1,968

1,532

Total revenue

13,695

12,210

27,546

24,126

Operating costs and expenses

Product costs

1,945

1,615

3,904

3,205

Research and development

3,774

3,512

7,136

7,150

Selling, general and administrative

3,847

3,394

7,500

6,860

Total operating costs and expenses

9,566

8,521

18,540

17,215

Operating income from continuing operations

4,129

3,689

9,006

6,911

Investment income

56

143

127

281

Other income

282

162

1,458

170

Impairment loss on investments

(129

)

(804

)

(129

)

(804

)

Other income (loss), net

209

(499

)

1,456

(353

)

Income from continuing operations before income taxes

4,338

3,190

10,462

6,558

Income tax provision

(918

)

(1,244

)

(2,794

)

(2,457

)

Income from continuing operations

3,420

1,946

7,668

4,101

Discontinued operations:

Income (loss) from discontinued operations, net of taxes

682

(344

)

682

1,261

Income (loss) on sale of discontinued operations, net of taxes

121

(933

)

Income (loss) from discontinued operations

682

(223

)

682

328

Net income

$

4,102

$

1,723

$

8,350

$

4,429

Basic income (loss) per share:

Continuing operations

$

0.23

$

0.11

$

0.52

$

0.23

Discontinued operations

0.05

(0.01

)

0.05

0.02

Net income

$

0.28

$

0.10

$

0.57

$

0.25

Diluted income (loss) per share:

Continuing operations

$

0.23

$

0.11

$

0.52

$

0.23

Discontinued operations

0.05

(0.01

)

0.05

0.02

Net income

$

0.28

$

0.10

$

0.56

$

0.25

Weighted average number of shares outstanding:

Basic

14,622

17,519

14,639

17,498

Diluted

14,914

17,632

14,871

17,575

SurModics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

March 31,
2013

September 30,
2012

(Unaudited)

Assets

Cash and short term investments

$

35,684

$

29,657

Accounts receivable

4,911

5,069

Inventories

3,364

3,524

Other current assets

1,692

822

Current assets of discontinued operations

129

883

Total current assets

45,780

39,955

Property and equipment, net

13,214

13,610

Long-term investments

27,506

28,433

Other assets

21,093

22,321

Total assets

$

107,593

$

104,319

Liabilities and Stockholders' Equity

Current liabilities

$

3,197

$

5,259

Current liabilities of discontinued operations

271

1,640

Total current liabilities

3,468

6,899

Other liabilities

2,140

2,432

Total stockholders' equity

101,985

94,988

Total liabilities and stockholders' equity

$

107,593

$

104,319

SurModics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

Six Months Ended
March 31,

2013

2012

(Unaudited)

Operating Activities:

Net income

$

8,350

$

4,429

Income from discontinued operations

(682

)

(1,261

)

Loss on sale of discontinued operations

933

Depreciation and amortization

1,446

1,480

Stock-based compensation

1,238

1,533

Gain on sale of available-for-sale securities and strategic investments

(1,458

)

(170

)

Net other operating activities

492

552

Change in operating assets and liabilities:

Accounts receivable

158

(244

)

Accounts payable and accrued liabilities

(1,366

)

(3,159

)

Income taxes

(1,322

)

2,739

Net change in other operating assets and liabilities

(31

)

(658

)

Net cash provided by operating activities from continuing operations

6,825

6,174

Investing Activities:

Net purchases of property and equipment